Stuart Therapeutics today announced the addition of Brian P. Ceresa, Ph.D. to the company’s Scientific Advisory Board. Dr. Ceresa is a Professor in the Department of Pharmacology and Toxicology at the University of Louisville School of Medicine, and also is a Member of James Graham Brown Cancer Center and an Associate Member of the Department of Ophthalmology and Visual Sciences, University of Louisville School of Medicine. He earned his PhD in Pharmacology from Vanderbilt University, and completed Postdoctoral Fellowships at the University of Iowa, Department of Physiology and Biophysics; and at The Scripps Research Institute, Department of Cell Biology. Dr. Ceresa is a leading researcher in the molecular mechanisms that regulate signaling by receptor tyrosine kinases. His research is particularly focused on the epidermal growth factor receptor (EGFR) and the receptor’s role in the regulation of cell growth, proliferation, differentiation and migration. The applications of Dr. Ceresa’s work include understanding the mechanisms of cancer development and progression, particularly through study of the overexpression and hyperactivity of receptors in normal and cancer cells. The Ceresa Lab uses a combination of biochemical, cell biological and in vivo techniques to better understand receptor signaling and regulation.
Dr. Ceresa’s work is directly applicable to Stuart Therapeutics’ development of therapies that impact cancer conditions and corneal tissue healing and repair. He is widely published on growth factor receptors and their role in cancer development, as well as corneal epithelial cell mechanisms.
“I look forward to working with the team at Stuart Therapeutics as a member of their Scientific Advisory Board, and advising them on their research and product development for PolyCol,” said Dr. Ceresa. “I believe that the PolyCol platform represents an exciting new opportunity to provide targeted therapies for a variety of clinical indications in an extremely flexible way.”
“We are pleased to welcome Dr. Ceresa to our Scientific Advisory Board,” said Eric Schlumpf, Stuart Therapeutics’ President and CEO. “His depth of expertise will be critical as we further develop the PolyCol technology in both corneal tissue disease conditions and oncology.”
About Stuart Therapeutics:
Stuart Therapeutics, established in 2017, is developing PolyCol, a unique therapeutic platform that offers improvements in health outcomes for a wide variety of medical and veterinary conditions. PolyCol is based on patented research from a major U.S. university, combined with additional intellectual property owned by Stuart Therapeutics.
Stuart Therapeutics’ mission is the development of new and meaningful therapies that improve
and extend the lives of people suffering from difficult to treat diseases.
For additional information about Stuart Therapeutics please visit the Company’s website at www.StuartTherapeutics.com or contact by phone via the information provided below.
Contact:
Stuart Therapeutics
www.StuartTherapeutics.com
(772) 678-7307
2336 SE Ocean Blvd, Suite 373
Stuart, FL 34996
